Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (771)	5/11/1999 9:39:00 PM
From: arnie h	Read Replies (1) \| Respond to of 1386

David: You make a number of cogent points and the situation is far from bleak. It is also far from being a strong one. The company had expected much higher sales and sales growth by this time and we have been given no explanation for the difference. Your point that the ability to be able to 'scape by' can add leverage for a HU 211 deal is especially meaningful. This is one of the main reasons I've been anxious about the growth of sales for Alrex and Lotemax and have raised this issue a number of times on the thread. Partners just don't hand out real money if you are in a weak position except in the case of a real bidding war. I don't see that or a deal would have already been struck. The comment I made about infusing money had to do with the fact that the company seems to have been able to tap a source who won't cause the kind of problems caused by the 2 previous infusions by hedge funds. If not a positive, it is at least not the same kind of negative. With regard to the intersection between short sellers and a deal for HU 211, I'll answer your question with a prediction; namely, short sales will drop to below 250,000 shares before any deal is struck for HU 211. Regards, Arnie